Previous 10 | Next 10 |
Wave Life Sciences press release ( NASDAQ: WVE ): Q2 GAAP EPS of -$0.62 misses by $0.08 . Revenue of $0.37M (-86.7% Y/Y). As of June 30, 2022, Wave had $148.2 million in cash, cash equivalents and short-term investments For further details see:...
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced program currently in development using an oligonucleotide to harness an endogenous enzyme for editing Data for ongo...
Wave Life Sciences ( NASDAQ: WVE ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.53 (+32.1% Y/Y) and the consensus Revenue Estimate is $3M (+7.9% Y/Y). Over the last 3 months, EPS estimates ...
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and confe...
Two new Breakout Stocks for Week 30 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +96.9% YTD. High frequency breakouts continue with peak gains in 1 of 4 picks above 10% led by TA gaining +13.1% and next top gains were in SP...
Two new Breakout Stocks for Week 29 with better than 10% short-term upside potential and one Dow 30 Picks. Average cumulative returns now up to +88.6% YTD. No picks broke 10% in less than a week with top gains in HOWL +9.4% and VRDN 6.5% and the Negative MDA trading signal continues f...
Two new Breakout Stocks for Week 28 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now up to +86.9% YTD. No picks broke 10% in less than a week and the Negative Momentum Gauge® warning signals continue negative through 27 out of the...
Gainers: 22nd Century Group (XXII) +29%. Wave Life Sciences WVE +16%. Codex DNA (DNAY) +13%. F-star Therapeutics (FSTX) +12%. Sorrento Therapeutics (SRNE) +12%. Losers: Athira Pharma ATHA -70%. Neptune Wellness Solutions NEPT -32%. 4D pharma (LBPS)...
Wave Life Sciences (NASDAQ:WVE) has disclosed a share purchase by 10% owner Ra Capital Management. Ra Capital Management bought over 9.48M shares of the company's ordinary shares at $2.15 in a transaction dated June 16, 2022. It now becomes the beneficial owner of 17,202,009 shares of the iss...
Wave Life Sciences (NASDAQ:WVE) priced an underwritten offering of 25.5M shares at an offering price of $2.15/share and to RA Capital Management, in lieu of ordinary shares, pre-funded warrants to purchase up to 7.09M shares. The per share offering price for the ordinary shares represent...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
Wave Life Sciences Ltd. Website:
2024-07-17 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...